Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Kymera Therapeutics (KYMR) over the last 6 years, with Q3 2025 value amounting to $87.3 million.

  • Kymera Therapeutics' Shares Outstanding (Diluted Average) rose 1467.87% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.3 million, marking a year-over-year increase of 1467.87%. This contributed to the annual value of $75.0 million for FY2024, which is 2857.59% up from last year.
  • Per Kymera Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $87.3 million for Q3 2025, which was up 1467.87% from $80.4 million recorded in Q2 2025.
  • In the past 5 years, Kymera Therapeutics' Shares Outstanding (Diluted Average) registered a high of $87.3 million during Q3 2025, and its lowest value of $45.1 million during Q2 2021.
  • In the last 5 years, Kymera Therapeutics' Shares Outstanding (Diluted Average) had a median value of $58.3 million in 2023 and averaged $62.9 million.
  • As far as peak fluctuations go, Kymera Therapeutics' Shares Outstanding (Diluted Average) surged by 17660.05% in 2021, and later skyrocketed by 712.63% in 2023.
  • Over the past 5 years, Kymera Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $48.0 million in 2021, then grew by 12.39% to $53.9 million in 2022, then rose by 8.22% to $58.4 million in 2023, then increased by 28.58% to $75.0 million in 2024, then grew by 16.33% to $87.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $87.3 million for Q3 2025, versus $80.4 million for Q2 2025 and $80.1 million for Q1 2025.